Innovative Alzheimer’s Research Presented by DiamiR and Aptorum
DiamiR Biosciences Corp., the developer behind advanced blood-based diagnostic tests for brain health, is stepping into the spotlight along with Aptorum Group Limited (NASDAQ: APM). This exciting collaboration brings forward two compelling poster presentations at an upcoming conference dedicated to Alzheimer's disease. These presentations are set to showcase cutting-edge research focusing on the potential of microRNAs as significant biomarkers for neurodegeneration.
Details of the Upcoming Presentations
Taking place during a pivotal section of the conference focusing on biomarkers of Alzheimer's, the poster presentations are scheduled for December 3, 2025. Held at the Hilton San Diego Bayfront, the event will serve as an essential platform for researchers and professionals to engage with the latest advancements in Alzheimer's diagnostics. These presentations will reflect the tireless research efforts and cooperation among leading academic institutions and Alzheimer’s research centers.
Poster Highlights
The first key poster, #225, is titled Developing microRNA classifiers enriched in brain and associated with inflammation in plasma samples to classify Cognitively Unimpaired, MCI, and AD study participants. This significant work was a collaboration with New York University’s Alzheimer’s Disease Research Center, showcasing how microRNA classifiers can aid in diagnosing various states of cognitive impairment.
Second Presentation Details
Poster #240 will delve into Characterization of stages of neurodegeneration using circulating brain-enriched and inflammation associated microRNAs. This research, conducted in cooperation with the University of Pennsylvania, underscores the transformative potential of microRNA analyses in understanding Alzheimer's progression.
Understanding the Importance of CTAD
The Clinical Trials on Alzheimer’s Disease (CTAD) Conference, established in 2008, serves as a landmark occasion for researchers dedicated to Alzheimer’s disease. This conference aims to foster dialogue, allow collaborative efforts, and elevate the standard of discussions surrounding clinical research in Alzheimer’s. With a robust peer-review process in place, CTAD has built a reputation for showcasing high-quality research, paving the way for significant advancements in the field.
About the Merger Between DiamiR and Aptorum
A pivotal development in 2025 was the announcement of a merger agreement between DiamiR and Aptorum. This all-stock transaction is anticipated to conclude in the first quarter of 2026, making DiamiR a wholly-owned subsidiary of Aptorum Group. This merger signifies a strategic move to consolidate resources and expertise in the rapidly evolving field of biopharmaceuticals, particularly concerning unmet medical needs in both Alzheimer’s research and broader medical landscapes.
About Aptorum Group
Aptorum Group Limited (NASDAQ: APM) is dedicated to the discovery and development of innovative therapeutic solutions addressing significant medical challenges. Their initiatives, particularly in oncology and infectious diseases, align with the growing demand for effective treatments in these areas. Their commitment to advancing health solutions is highlighted by their proactive involvement in research discussions and collaborations.
About DiamiR Biosciences
DiamiR Biosciences stands out as a pioneer in developing minimally invasive diagnostic tests for brain health. With a robust platform technology safeguarded by over 50 patents worldwide, they focus on utilizing microRNA signatures to monitor disease progression and treatment efficacy. DiamiR collaborates with leading academic institutions and biopharma companies, contributing to the collective fight against neurodegenerative diseases.
Frequently Asked Questions
What is the focus of the upcoming presentations by DiamiR and Aptorum?
The presentations will revolve around the use of microRNAs as biomarkers for Alzheimer's disease, showcasing significant research findings.
When and where is the CTAD Conference taking place?
The conference is scheduled for December 1-4, 2025, at the Hilton San Diego Bayfront and online.
What is the nature of the merger between DiamiR and Aptorum?
This merger is an all-stock transaction, expected to close in the first quarter of 2026, with DiamiR becoming a subsidiary of Aptorum.
How is DiamiR contributing to the field of Alzheimer's research?
DiamiR focuses on developing blood-based diagnostic tests to aid in early detection and monitoring of brain health conditions.
What does Aptorum Group specialize in?
Aptorum Group is dedicated to developing therapeutic solutions for diseases with unmet medical needs, particularly in oncology and infectious diseases.